Jennison Associates LLC Acquires 494,216 Shares of Elanco Animal Health Incorporated $ELAN

Jennison Associates LLC lifted its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 18.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,120,665 shares of the company’s stock after buying an additional 494,216 shares during the quarter. Jennison Associates LLC’s holdings in Elanco Animal Health were worth $74,678,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. UBS Group AG grew its stake in Elanco Animal Health by 56.7% in the 3rd quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after buying an additional 5,961,457 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its position in shares of Elanco Animal Health by 11.8% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock worth $797,197,000 after acquiring an additional 3,717,404 shares in the last quarter. Invesco Ltd. lifted its position in shares of Elanco Animal Health by 336.0% during the fourth quarter. Invesco Ltd. now owns 4,789,037 shares of the company’s stock worth $108,376,000 after acquiring an additional 3,690,735 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of Elanco Animal Health in the first quarter worth $66,390,000. Finally, Artemis Investment Management LLP bought a new position in shares of Elanco Animal Health in the fourth quarter worth $55,693,000. 97.48% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Piper Sandler reiterated an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Citigroup raised their target price on Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Weiss Ratings lowered Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. Wall Street Zen lowered Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. Finally, JPMorgan Chase & Co. upped their price target on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $28.55.

Elanco Animal Health Stock Up 0.0%

ELAN opened at $25.84 on Monday. The firm has a market capitalization of $12.91 billion, a P/E ratio of -51.68, a price-to-earnings-growth ratio of 1.69 and a beta of 1.68. Elanco Animal Health Incorporated has a one year low of $13.39 and a one year high of $27.72. The company has a fifty day moving average price of $23.63 and a 200-day moving average price of $23.90. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.16 and a quick ratio of 1.12.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The firm’s revenue was up 14.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Equities research analysts expect that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current fiscal year.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, CEO Jeffrey N. Simmons purchased 4,971 shares of the company’s stock in a transaction dated Friday, May 15th. The stock was purchased at an average price of $20.09 per share, for a total transaction of $99,867.39. Following the transaction, the chief executive officer owned 171,971 shares in the company, valued at $3,454,897.39. The trade was a 2.98% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Rajeev A. Modi acquired 4,911 shares of the business’s stock in a transaction dated Friday, May 15th. The shares were acquired at an average cost of $20.35 per share, with a total value of $99,938.85. Following the acquisition, the insider directly owned 160,812 shares of the company’s stock, valued at $3,272,524.20. This represents a 3.15% increase in their position. The SEC filing for this purchase provides additional information. 1.14% of the stock is owned by corporate insiders.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.